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Abstract There is an urgent need to identify more
accurate prognostic biomarkers in melanoma patients,
particularly in those with metastatic disease. This study
aimed to identify melanoma and leukocyte surface antigens
predictive of survival in a prospective series of AJCC stage
IIIb/c melanoma patients (n = 29). Live cell suspensions
were prepared from melanoma metastases within lymph
nodes (LN). The suspensions were immuno-magnetically
separated into CD45? (leukocyte) and CD45- (non-
hematopoietic, enriched melanoma cell) fractions. Surface
antigens on CD45- and CD45? cell populations were
profiled using DotScanTM microarrays (Medsaic Pty. Ltd.)
and showed differential abundance levels for 52 and 78
antigens respectively. Associations of the surface profiles
with clinicopathologic and outcome data (median follow-
up 35.4 months post LN resection) were sought using
univariate (log-rank test) and multivariate (Wald’s test;
modelled with patient’s age, gender and AJCC staging at
LN recurrence) survival models. CD9 (p = 0.036), CD39
(p = 0.004) and CD55 (p = 0.005) on CD45? leukocytes
were independently associated with distant metastasis-free
survival using multivariate analysis. Leukocytes with high
CD39 levels were also significantly associated with
increased overall survival (OS) in multivariate analysis
(p = 0.016). LNs containing leukocytes expressing CD11b
(p = 0.025), CD49d (p = 0.043) and CD79b (p = 0.044)
were associated with reduced OS on univariate analysis.
For enriched melanoma cells (CD45- cell populations), 11
surface antigens were significantly correlated with the
disease-free interval (DFI) between diagnosis of culprit
primary melanoma and LN metastasis resection. Nine
antigens on CD45? leukocytes also correlated with DFI.
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Following validation in independent datasets, surface
markers identified here should enable more accurate
determination of prognosis in stage III melanoma patients
and provide better risk stratification of patients entering
clinical trials.
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Abbreviations:
AJCC American Joint Committee on Cancer
DFI disease-free interval
DMFS distant metastasis-free survival
ECM extracellular matrix
HR hazard ratio
LN lymph node
MIA Melanoma Institute Australia
MDSC myeloid-derived suppressor cell
NK natural killer
OS overall survival
TGF-b1 transforming growth factor-b1
Introduction
Melanoma is a major cause of morbidity and mortality in
many Western countries and its incidence is increasing [1].
In these populations, melanoma is one of the most common
cancers amongst young adults and is a major public health
problem [2, 3]. Compared with other cancers, melanoma has
a propensity for metastasis early in disease progression, even
from thin (early stage) primary tumors [4]. Nevertheless,
when detected and treated early, melanoma has a high cure
rate. Mortality in melanoma is usually a consequence of
metastatic spread. A detailed melanoma staging system was
developed by the American Joint Committee on Cancer
(AJCC) to stratify patients into prognostic groups, taking
into account the principal prognostic factors including pri-
mary tumor characteristics (such as tumor thickness, ulcer-
ation, mitotic rate) and the presence, number and size of
loco-regional and distant metastases [5]. However, outcomes
for patients within individual AJCC stage sub-categories can
be vastly different, particularly for those with metastatic
disease. For example, 50 % of patients who present with
clinically palpable regional lymph node (LN) metastases
(AJCC stage IIIc disease) will be dead within 2 years.
However, 50 % of those who are still alive at 2 years will live
for more than 20 years. Identification of parameters and
biomarkers that can collectively predict prognosis for AJCC
stage III patients would facilitate more accurate risk strati-
fication, rational selection of patients who may benefit from
adjuvant therapies, and development of screening and follow
up protocols.
Many studies have sought to identify protein biomarkers,
including surface antigens that can be utilized for prognosis of
primary melanoma [6, 7]. Whilst some biomarkers correlate
with melanoma progression and survival, few have shown
significance independent of other well known and more easily
measured prognostic parameters (such as tumor thickness)
and even less have been validated in independent datasets [8–
20]. An extensive immuno-phenotype (surface profile) using
antibody microarrays may identify disease signatures able to
predict the clinical behavior of melanoma (e.g., likely sites of
metastatic spread) and patient outcome. Most antibody
microarrays detect soluble proteins. By contrast, DotScanTM
(Medsaic Pty. Ltd., Sydney, Australia) captures live cells that
express the corresponding antigens on their surface. The data
obtained correlate well with antigen levels determined by flow
cytometry [21–23]. DotScanTM has been applied to a variety
of clinical samples, including leukaemia, lymphoma,
peripheral blood leukocytes from HIV and heart transplant
recipients, and colorectal cancer specimens [23–29]. Anti-
bodies printed on the microarray used in the current study
were selected based on their association with melanoma dis-
ease progression and/or prognosis. Some of these surface
molecules are important targets for anti-melanoma drugs,
although their functions have not been fully elucidated.
In the present study, we have used an extended DotScanTM
microarray [25] to detect surface antigen profiles of live
melanoma cells and leukocytes from fresh surgically excised
metastatic melanoma LN tumors (AJCC stage IIIb/c disease)
and interrogated the findings with prospectively collected
clinical and follow up data from each patient. We identified a
number of differentially abundant antigens associated with
distant metastasis-free and overall survival (OS). In addition,
we have identified antigens associated with a prolonged dis-
ease-free interval between initial primary melanoma diagno-
sis and resection of nodal metastatic disease.
Experimental procedures
Melanoma lymph node metastases
Melanoma LN metastases (n = 38) were obtained from the
Melanoma Institute Australia (MIA) Bio-specimen Bank
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with written informed patient consent and IRB approval
(Sydney South West Area Health Service institutional
ethics review committee (RPAH Zone) Protocol Nos.,
X06-0140, X08-0155/HREC 08/RPAH/262, X11-0023/
HREC 11/RPAH/32 and X07-0202/HREC/07/RPAH/30).
Fresh tumor samples were examined by a specialist mela-
noma pathologist (RAS) and carefully macro-dissected
from non-tumor tissues avoiding necrotic areas and normal
lymph node tissue. A high-percentage melanoma tumor
content ([80 %) and low necrosis (\20 %) were verified
by examining hematoxylin and eosin-stained sections and
immunohistochemistry for melanoma antigens S-100 pro-
tein, HMB45 and MelanA/MART-1.
The fresh metastatic melanoma LN tumors were col-
lected prospectively over a 13-month period from February
2009 and subsequent clinical follow-up data spaning
24.3–43.1 months (median 35.4 months) post LN resection
was obtained. Nine patients were excluded from the study
due to a high level of necrosis and poor cell viability
(n = 3), a non-melanoma diagnosis following subsequent
histopathology (n = 3) or evidence of distant metastases at
diagnosis of the culprit primary melanoma (n = 3; stage
IV at initial diagnosis). The remaining 29 cases were
analyzed for demographic, primary tumor and metastasis
pathologic and survival data as detailed in Table 1. As of
May 2013, 13 patients were alive [11 with no sign of
recurrence (NSR) and 2 with melanoma], 15 patients had
died of melanoma and 1 patient had died of unrelated
causes. One patient had synchronous AJCC stage IV dis-
ease at the time of LN recurrence and was excluded from
the survival analyses. Patients with occult primary disease
or with previous LN involvement were excluded from the
DFI correlation analysis. Despite good cell viability, two
patient samples had poor binding of cells to the microarray
and were used for Western blot analysis.
In summary, we investigated the associations of CD45-
enriched melanoma cell (n = 25) and CD45? leukocyte
(n = 23) immuno-profiles in melanoma patients with dis-
tant metastasis-free survival (DMFS) and OS post LN
resection of stage IIIb/c disease. Immuno-profiles of
CD45- enriched melanoma cells (n = 20) and CD45?
leukocytes (n = 19) were also correlated with DFI (time
between diagnosis of culprit primary melanoma and LN
resection; see Supplementary Table 1).
Preparation of viable, single cell suspensions
Fresh tumor samples were placed in Hanks’ balanced salt
solution (HBSS; Sigma-Aldrich, St. Louis. MO, USA) at
4 C and processed within 16 h to ensure cell viability.
Samples were finely diced with a scalpel blade and incu-
bated in a dissociation buffer containing 1 % (w/v) colla-
genase type IV (Worthington, Lakewood, NJ, USA) and
0.2 % (w/v) DNase I (bovine pancreas; Sigma-Aldrich) in
HBSS at 37 C for 1 h, with gentle vortexing every
15 min. The semi-digested tissue was then passed through
a fine wire mesh strainer and the resulting suspension
centrifuged (450 9 g, 4 C, 5 min). Small aggregates were
removed using 200 lm and then 50 lm Filcon cup filters
(BD Biosciences, San Jose, CA, USA), resulting in a sin-
gle-cell suspension with 70–90 % viability, that was frozen
at -80 C in fetal calf serum (FCS) with 10 % DMSO
until required.
Separation of leukocytes from melanoma cells
Prior to surface profiling, samples were thawed and pel-
leted (4009g, 4 C, 5 min) and the cells resuspended in
RPMI growth medium with 0.2 % (w/v) DNase I for
10 min at room temperature. Leukocytes were bound to
CD45 antibody microbeads (Miltenyi Biotec, Auburn, CA,
USA) and separated from cell suspensions using an Auto-
MACSTM Pro Separator (Miltenyi Biotec) as per the
manufacturer’s instructions. Briefly, 2 9 107 cells were
incubated with 40 lL anti-CD45 microbeads in a buffer
containing PBS with 0.1 % BSA, 2 mM EDTA and 2 %
AB serum at 4 C for 10 min. Cells were diluted, pelleted
(3009g, 4 C, 10 min), resuspended in 500 lL of the
above buffer and passed through a 50 lm filter before
removal of magnetic beads with attached CD45? cells
using the ‘deplete’ setting on the AutoMACSTM Pro Sep-
arator. To confirm depletion of the CD45? cells, a mela-
noma LN cell suspension was labelled with mouse
monoclonal anti-CD45-PE or anti-IgG2a-PE (Miltenyi
Biotec) and analyzed on a FACScaliburTM (BD Biosci-
ences) before and after immuno-magnetic separation
(Supplementary Fig 1).
Capture of cells on DotScanTM microarrays
The microarrays were constructed as duplicate dots (10 nl)
on nitrocellulose-coated slides (Grace Bio-labs Inc., Bend,
OR, USA) as previously described [25]. All array anti-
bodies were specific to extracellular domain sequences
where possible, if not the full-length protein. However,
antibody avidity might be reduced following its immobi-
lization to the nitrocellulose slide. CD45? and CD45- live
cell suspensions were suspended at a density of 1.3 9 107/
ml in growth medium (RPMI with 10 % FCS and 2 %
heat-inactivated human AB serum) and incubated on pre-
moistened microarrays in a humidified chamber at 37 C
for 30 min. Captured cells were fixed in 3.7 % formalde-
hyde for 30 min at room temperature and washed in PBS.
Arrays were imaged directly with an optical scanner
(Medsaic Pty Ltd) without staining or labelling, and ana-
lyzed using DotScanTM software (Medsaic Pty Ltd) [23].
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This software quantifies the density of cell binding on each
antibody dot above background levels, on an 8-bit scale
from 1–256. Dot intensities on an array reflect the pro-
portion of cells expressing each antigen and/or the level of
expression of a particular antigen per cell. The average
numbers of cells bound to each dot, determined micro-
scopically, correlate well with average binding density
values. The number of cells captured on an antibody dot in
the microarray also depends on the affinity of the antibody-
antigen interaction.
Statistical analysis of antibody microarray results
Cell binding densities were corrected for background and
isotype-control binding and the duplicate array information
was averaged and log2-transformed. Microarray data,
consisting of 52 antigens for melanoma (CD45-) samples
and 78 antigens for leukocytes (CD45?), were median
normalized separately. DMFS was calculated from the
time of LN resection to appearance of distant metastasis or
last clinical follow-up. OS was calculated from the time of
LN resection, to last clinical follow-up or death. Univariate
(log-rank test) and multivariate (Wald’s test) survival
models were used to assess associations between antigen
levels and patient survival (DMFS and OS). Due to the
small patient numbers (enriched melanoma cells, n = 25
and leukocytes, n = 23), we were unable to include all
clinical variables in a single survival model. Instead, we
restricted our attention to the patient’s age, gender and
AJCC stage at LN resection (stage IIIb or IIIc) because
these are the strongest known predictors of outcome in
AJCC stage III melanoma patients. For patients with
multiple primary melanomas (n = 3), the culprit primary
was designated on the basis of the presence of the most
adverse prognostic factors and its anatomic site, due to a
greater likelihood that it was the source of the metastatic
disease, as previously described [30, 31]. We censored
patients who died of other causes, and for the DMFS
analysis, patients who had no distant metastasis. For the
DFI correlation analysis, Pearson’s r2 values were calcu-
lated to determine the relationship between surface antigen
levels and the time (in months) between the culprit primary
melanoma diagnosis and LN resection of stage III meta-
static disease.
Western blotting
Total protein extracts were made from CD45? cell popu-
lations from 13 LN samples (see Supplementary Table 1)
by lysing cells in a denaturing urea buffer containing 7 M
urea, 2 M thiourea, 40 mM Tris, 65 mM DTT supple-
mented with 0.1 mM phenylmethylsulfonyl fluoride
(PMSF) and centrifuged (16,0009g, 15 min, 4 C). Due toTa
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limited sample availability, the level of one surface antigen
(CD55) was confirmed by Western blotting. Proteins were
separated by 10 % SDS-PAGE and transferred to a PVDF
membrane at 400 mA for 1 h using a CriterionTM Blotter
(BioRad, Hercules, CA, USA). The membrane was blocked
in 5 % (w/v) skim milk and incubated overnight at 4 C
with a 1:5,000 dilution of rabbit monoclonal antibody
against CD55 (EPR6689, Epitomics, Inc., Burlingame, CA,
USA) and 1:10,000 dilution of mouse monoclonal antibody
against succinate dehydrogenase subunit A (SDHA; Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Mem-
branes were then incubated with donkey, anti-rabbit (Ab-
cam, Waterloo, NSW, Australia) and goat, anti-mouse
(Santa Cruz) secondary antibodies conjugated to horse-
radish peroxidase for 2 h at room temperature. Bands were
visualized with ECL detection reagent and imaged using
chemiluminescence film (GE Healthcare, Piscataway, NJ,
USA). Bands were quantified using ImageQuantTL density
analysis software (GE Healthcare). An average of the
density of SDHA and the total protein stain was used as an
internal loading control. To confirm the association with
DMFS, CD55 level ratios were tested using the log-rank
test described above.
Results
Surface profiles of melanoma LN metastases
Single cell suspensions of 29 metastatic melanoma LN
specimens were immuno-magnetically separated to isolate
CD45? leukocytes and enrich for melanoma cells
(CD45-). Cell separation was confirmed by flow cytometry
(Supplementary Fig. 1). This together with a failure of the
CD45- cells to bind CD45, CD45RA and CD45RO or
other leukocyte specific antigens on the arrays confirmed
the effectiveness of the cell separation. Adequate cell
numbers (4 9 106 cells), viability ([70 %) and binding
were achieved for CD45- and CD45? cell populations
from 26 to 24 patient samples, respectively (See Fig. 1 for
optical scan of cell binding patterns). Cell binding to 52
and 78 antibodies was observed for CD45- enriched
Fig. 1 Immuno-phenotypes of cell suspensions isolated from lymph
node tumors resected from stage III metastatic melanoma patients.
a Antibody key for the microarray, printed in duplicate on nitrocel-
lulose slides. Antibody key is zone framed in grey on (b–g). (b–
d) Antibody binding patterns of enriched melanoma cells (CD45-)
from patients 19, 13 and 8 respectively. (e–g) Antibody binding
patterns of leukocytes attached to CD45? magnetic beads (CD45?)
isolated from patients 19, 25 and 7 respectively. The numbers in
(a) refer to antibodies against corresponding CD antigens; IgG1,
IgG2a, IgG2b, IgG3 and IgM are murine isotype control antibodies
tested at the concentrations shown in lg/mL; TCR a/b, TCR c/d,
HLA-DR, FMC7, k and k are antibodies against T-cell receptors a/b
and c/d, HLA-DR, FMC-7, kappa and lambda immunoglobulin light
chains, respectively. A border of CD44/CD29 alignment dots is
shown around the duplicate microarrays of (b–g)
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melanoma cells and CD45? leukocytes, respectively.
Normalization and subsequent analyses were performed
using this these data. Some antigens were expressed at
variable levels on all CD45- fractions, e.g., CD29, CD44,
CD51, CD63, CD71, CD146 and CD151. Although the
leukocyte (CD45?) antigen profiles were more diverse,
perhaps reflecting the heterogeneity of the cell populations,
as expected, there was consistent binding to the antibodies
for CD45, and CD45RA and/or CD45RO for all patient
samples.
DMFS and OS analyses
In leukocyte (CD45?) fractions, high levels of CD9 were
associated with decreased DMFS on both univariate and
multivariate analyses (HR = 2.67, p = 0.039 and
HR = 3.73, p = 0.036, respectively; Fig. 2). In contrast,
increased levels of CD39 and CD55 were associated with
increased DMFS on univariate (HR = 0.29 and 0.28,
p = 0.019 and 0.006, respectively) and multivariate anal-
yses (HR = 0.01 and 0.10, p = 0.004 and 0.005, respec-
tively). A significant association between increased levels
of CD55 and DMFS was confirmed by Western blotting
(HR = 2.8; p = 0.008; see Fig. 4). The CD45- enriched
melanoma cells displayed differential binding to CD117 (c-
KIT), with higher levels associated with decreased DMFS
on univariate analysis with borderline significance
(HR = 1.56; p = 0.07).
Higher levels of CD39 on CD45? leukocytes were also
significantly associated with increased OS using both uni-
variate and multivariate models (HR = 0.29, p = 0.045
and HR = 0.10, p = 0.016, respectively; Fig. 3). There is
a documented synergy between CD39 and CD73 activities
[23]. We found increased CD73 levels associated with
DMFS and OS, with marginal significance (p = 0.08 and
0.13, respectively). When CD73 and CD39 levels were
modelled together, CD39 remained significantly associated
with DMFS (p = 0.027). Increased levels of CD11b,
CD49d and CD79b on CD45? leukocytes were associated
with reduced OS (HR = 2.72, 2.46, 1.76, p = 0.025,
0.043, 0.044, respectively). However these associations
were not statistically significant on multivariate analysis.
Leukocyte results are summarised in Table 2 and survival
plots for DMFS and OS are depicted in Figs. 2 and 3. No
statistically significant association with OS was found for
the 58 antigens tested on CD45- enriched melanoma cells.
DFI correlation analyses
A proportion of patients with primary melanoma carry a
risk for recurrence and distant metastases after a symptom-
free period that can span decades, despite favourable
prognostic determinants from their primary tumor. The
relationship between this DFI, defined as the time between
primary melanoma resection and resection of nodal
metastases (spanning 3.6–247.2 months in this study) and
antigen levels was also investigated. Enriched melanoma
(CD45-) cells showed higher levels of 11 surface antigens
in resected LNs from metastatic melanoma patients with a
prolonged DFI (p \ 0.05; average r2 of 0.484; see Sup-
plementary Fig. 2a and Table 3). Five of these antigens are
cell adhesion molecules, i.e., integrins (CD29, CD49c),
tetraspanin CD63, CD56 (neural adhesion molecule,
NCAM) and CD107a (lysosome-associated membrane
protein 1). For CD45? leukocyte fractions, nine antigens
were correlated with shorter DFI (p \ 0.05; average r2 of
-0.590; Supplementary Fig. 2b and Table 3). Of these,
eight antigens are related to T cell immunity, i.e., CD7,
CD8, CD43, CD54, CD56, CD103, CD134 and CD166.
Discussion
Our novel methodology combines immuno-magnetic cell
separation with surface antigen profiling (partial membrane
proteome) to profile separated leukocyte (CD45?) and
enriched melanoma cell (CD45-) populations. Metastatic
melanoma is highly immunogenic and by profiling leuko-
cytes separately, we can understand how melanoma cells
might escape or diminish immune system control within
LNs and progress to metastatic disease. Some antigens
showed limited binding or were undetected across all
CD45? or CD45- cell populations and were removed from
the analyses. Low cell capture may be due to low antigen
levels, inaccessible antigen epitopes or a reduced affinity of
antibodies following immobilization on nitrocellulose.
Surface antigens significantly associated with DMFS, OS
and DFI are discussed below.
Survival analyses
Leukocyte antigens associated with reduced survival
Patients with shorter OS showed enhanced levels of
CD79b, part of the B-cell receptor complex (BCR),
implicating an elevation of B-lymphocytes in LNs resected
from stage III metastatic melanoma patients with poor
survival outcomes. De novo lymphatic formation or lym-
phangiogenesis is associated with cancer metastasis [32–
34]. B-lymphocyte accumulation within draining LNs is
required for LN lymphatic sinus expansion in response to
tumor growth and B-cell-associated lymphangiogenesis is
required to increase lymph flow through the tumor-draining
LNs [35]. These changes could actively promote tumor
dissemination through the lymphatic system [36]. In mur-
ine models of squamous cell carcinoma, wild-type mice
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showed tumor draining LN B-cell accumulation and lym-
phangiogenesis and the extent of these alterations predicted
progression from benign papillomas to metastatic carci-
nomas [37]. Primary melanomas prepare tumor-draining
LNs for the seeding of metastatic disease by stimulating
lymphangiogenesis and dampening sentinel node immunity
prior to the arrival of malignant cells [35, 38]. A multi-
variate risk analysis revealed that tumor lymphangiogene-
sis was the most sensitive prognostic marker for melanoma
sentinel LN metastasis [39]. Here, an accumulation of
Fig. 2 Univariate cox proportional hazard models were used to
evaluate associations between surface antigen levels and distant
metastasis-free survival (DMFS). For graphical representation, plot-
ted variables were dichotomized based on median antigen levels,
0 = low, 1 = high. Increased levels of (a) CD9 on CD45? leukocytes
were significantly associated with with distant metastasis and poor
survival outcomes. Conversely, higher levels of (b) CD39 and
(c) CD55 on CD45? leukocytes were associated with DMFS
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B-lymphocytes, indicated by elevated CD79b, may be
related to lymphangiogenesis, increased lymph flow and
subsequent tumor dissemination in stage III metastatic
melanoma patients with reduced OS. Interestingly, pro-
tective cell-mediated immunity provoked by adenoviral-
based cancer vaccines is enhanced in the absence of
B-cells, suggesting that a therapeutic regimen that includes
depletion of B-lymphocytes may be beneficial [40].
We detected higher levels of integrins aM (CD11b) and
a4 (CD49d) on CD45
? leukocytes in LN tumors from
Fig. 3 Univariate cox proportional hazard models were used to
evaluate associations between surface antigen levels and overall
survival (OS). For graphical representation, plotted variables were
dichotomized based on median antigen levels, 0 = low, 1 = high.
Increased levels of (a) CD11b, (b) CD79b and (c) CD49d on CD45?
leukocytes were significantly associated with reduced overall sur-
vival, whereas higher levels of (d) CD39 was associated with
increased survival
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patients with reduced OS. CD11b is found primarily on
innate immune cells of myeloid lineage, and plays impor-
tant roles in cell adhesion, migration, chemotaxis, and
phagocytosis [41]. Melanoma cell extravasation was
decreased following a reduction in integrin aMb2 levels on
polymorphonuclear neutrophils by functional blocking of
IL-8 binding [42], implicating CD11b in melanoma
metastasis. Myeloid-derived suppressor cells (MDSCs) are
over-produced in tumor-bearing hosts, constituting
approximately 5 % of total cells in tumors [43]. MDSCs
are CD11b?/Gr-1? (marker for granulocytes) and con-
tribute significantly to immune escape, intravasation and
angiogenesis [44]. These potent immunosuppressors can
elicit systemic effects on secondary lymphoid organs as
well as local effects within the tumor microenvironment
[44] and can compromise the efficacy of cancer immuno-
therapy [45, 46]. CD11b? MDSCs were enriched in mel-
anomas and lymphatic organs during tumor progression
[47]. Recently, two sub-populations of MDSCs were
described, based on the expression of CD49d. The CD49d?
subset of MDSCs is mainly monocytic and suppresses
antigen-specific T cell proliferation in a nitric oxide-
dependent mechanism, more potently than CD11b?/
CD49d- MDSCs [48]. The association between reduced
OS and increased levels of CD11b? and CD49d? on leu-
kocytes from LNs containing metastatic melanoma may be
attributed to MDSCs capable of potentiating local
immunosuppression.
Table 2 Leukocyte antigens significantly associated with survival
Acc. #a Antigen/protein
name
Univariate Multivariated
HRb p valuec HRb p valuee
Distant metastasis-free survival
P12926 CD9 (tetraspanin-29) 2.67 0.039 3.73 0.036
P49961 CD39 (ecto-ATPase
diphosphohydro-
lase 1)
0.29 0.019 0.010 0.004
P08174 CD55 (complement
decay-accelerating
factor)
0.28 0.006 0.098 0.005
Overall survival
P11215 CD11b (integrin aM) 2.72 0.025 1.75 [0.2
P49961 CD39 (ecto-ATPase
diphosphohydro-
lase 1)
0.29 0.045 0.099 0.016
P13612 CD49d (integrin a4) 2.46 0.043 1.22 [0.2
P40259 CD79b (B-cell antigen
receptor complex-
associated protein b
chain)
1.76 0.044 1.36 [0.2
a Accession numbers were obtained from UniProtKB/Swiss-Prot
knowledgebase (www.uniprot.org)
b HR Hazard ratio
c Log-rank test, significance level p \ 0.05
d Multivariate survival model, including age, gender and AJCC stage
at lymph node recurrence
e Wald test, significance level p \ 0.05
Table 3 Antigens with significant correlation to the disease-free
interval
Acc. #a Antigen/protein name r2 b p valuec
CD45 enriched melanoma cells
P05556 CD29 (Integrin b1) 0.494 0.0267
P28906 CD34 (Hematopoietic progenitor
cell antigen CD34)
0.489 0.0295
P28907 CD38 (ADP-ribosyl cyclase 1) 0.451 0.0460
P17301 CD49c (Integrin a3) 0.462 0.0400
P13591 CD56 (Neural cell adhesion
molecule 1; NCAM1)
0.452 0.0454
P13987 CD59 (Membrane attack complex
inhibition factor)
0.485 0.0301
P02786 CD71 (Transferrin receptor protein
1)
0.462 0.0400
P04216 CD95 (Apoptosis-mediating surface
antigen FAS)
0.593 0.0058
P08962 CD63 (Tetraspanin-30; Lysosomal-
associated membrane protein 3;
Melanoma-associated antigen
ME491)
0.475 0.0344
P11279 CD107a (Lysosome associated
membrane protein 1; LAMP-1)
0.489 0.0286
P41217 CD200 (OX-2 membrane
glycoprotein)
0.472 0.0358
CD45? Leukocytes
P09564 CD 7 (T-cell antigen CD7) -0.542 0.0164
CD 8 (T-cell glycoprotein CD8) – a
(Acc. # P01732) and b (Acc. #
P10966) chains
-0.677 0.0014
P16150 CD 43 (Leukosialin) -0.481 0.0370
P05362 CD 54 (Intercellular adhesion
molecule 1; ICAM1)
-0.642 0.0030
P13591 CD 56 (Neural cell adhesion
molecule 1; NCAM1)
-0.522 0.0219
P11911 CD 79a (Surface IgM-associated
protein)
-0.523 0.0217
P38570 CD 103 (Integrin E) -0.550 0.0146
P43489 CD 134 (Tumor necrosis factor
receptor superfamily member 4)
-0.614 0.0052
Q13740 CD 166 (Activated leucocyte cell
adhesion molecule)
-0.758 0.0002
a Accession numbers were obtained from UniProtKB/Swiss-Prot
knowledgebase (www.uniprot.org)
b Pearson product momentum coefficient, r2. r2 [ 0 is indicative of a
positive relationship between antigen expression levels and a long
disease-free interval, whereas r2 \ 0 describes decreased antigen
levels associated with a short disease-free interval
c Unadjusted p values, significance level p \ 0.05
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Levels of CD9 were increased on CD45? leukocytes
isolated from LNs resected from melanoma patients with
reduced DMFS. CD9 is a tetraspanin, expressed on
immune cells of lymphoid and myeloid lineages. By
treating peripheral natural killer (NK) cells with trans-
forming growth factor (TGF)-b1 under hypoxic culture
conditions, Cedeira et al. generated a population of CD9?
NK cells that secreted pro-angiogenic factors and have
reduced cytotoxicity [49]. TGF-b1 serum levels positively
correlate with melanoma stage and higher levels are
prognostic for reduced OS [50]. NK cells that express CD9
were thought to only occur in the female reproductive
system, however a CD9? NK cell population was recently
detected in the peripheral blood of metastatic melanoma
patients [51]. Altered NK cell function is a component of
global immune dysregulation that occurs in advanced
malignancies and a number of NK cell-based immuno-
therapies of melanoma are under investigation. Further
analysis of the role of CD9? leukocytes in progression of
metastatic melanoma is warranted.
Leukocyte antigens associated with increased survival
Higher CD55 (decay-accelerating factor) levels on leuko-
cytes were associated with longer DMFS on univariate and
multivariate analyses (p = 0.006 and 0.005), a finding
confirmed by Western blot analysis (Fig. 4; p = 0.008).
CD55 is a ubiquitous complement regulatory protein that is
critical for protection from bystander complement-medi-
ated attack. Enhanced levels of CD55 may simply protect
leukocytes from complement-mediated lysis. Interestingly,
in our recent comprehensive proteomic analyses of lymph
nodes resected from stage IIIc melanoma patients, several
complement proteins (complement C3, clustin and com-
plement component 1Q sub-component-binding protein)
were differentially abundant between patients with good
([4 years survival) and poor (\1 year survival) prognoses
(n = 33). Moreover, the top ranking (FDR \ 0.01) path-
way maps generated by MetaCoreTM (GeneGOTM, Encin-
itas, CA, USA) involved complement pathways (S. Mactier
et al. unpublished data, 2013). CD55 also co-stimulates
T-cells when engaged and cross-linked by antibodies [52,
53]. CD55 is also a ligand for CD97 and may be required to
stabilize T-cell receptor-MHC engagement to enhance
T-cell function [54]. Although this finding was confirmed
using Western blot (n = 13; 2 patients independent of
microarray analysis), investigation of CD55 antigen levels
on leukocytes in a larger patient cohort is required.
High levels of CD39 (Ecto ATP-diphosphohydrolase 1)
on CD45? leukocytes were associated with increased OS
and DMFS. CD39 is expressed by a broad range of
immune cells and catalyzes the sequential hydrolysis of
ATP to AMP that is further degraded to anti-inflammatory
adenosine. In the immune system, extracellular ATP
functions as a ‘‘natural adjuvant’’ that exhibits multiple
pro-inflammatory effects and is known to boost immune
responses in the tumor microenvironment. Deletion of
CD39 in a murine model abrogated angiogenesis, leading
to reduced growth and metastasis of subcutaneous mela-
noma tumors [55]. However, our results show that the
presence of higher CD39 on CD45? leukocytes confers a
survival advantage. In the context of LN metastases,
reduced CD39 levels would allow extracellular ATP to
trigger a more pronounced inflammatory response [56]
that can induce lymphangiogenesis and promote tumor
cell dissemination [36]. Therefore, opposed to the docu-
mented immunosuppressive properties, higher CD39 lev-
els in patients with longer DMFS and OS may reflect
reduced lymphatic dissemination of metastatic melanoma.
As CD73 works in concert with CD39 to catalyze the
conversion of AMP to adenosine [57], we examined
levels of CD73 in our dataset. Increased CD73 on CD45?
leukocytes were associated with DMFS with marginal
significance. Although CD39 and CD73 require further
investigation in a larger patient cohort, we have observed
Fig. 4 Western blot verifying
increased CD55 on CD45?
leukocytes fractionated from
Stage III metastatic melanoma
patients with distant metastasis-
free survival (HR = 2.8;
p = 0.008). Succinate
dehydrogenase subunit A
(SDHA) and total protein stains
were used as loading controls
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a trend of increased co-expression levels on CD45? leu-
kocytes from patients with longer DMFS.
CD117 is associated with distant metastasis and poor
survival on enriched melanoma cells
Increased levels of the receptor tyrosine kinase CD117 (c-
KIT) on enriched melanoma cells (CD45-) were associated
with distant metastasis and poor survival outcomes but this
was not statistically significant (p = 0.07). The reversible
expression of surface antigens on melanoma cells [58] as
well as the presence of other non-hematopoietic cell types
could explain the limited stratification of the CD45- cell
population obtained in our study.
Surface antigens associated with a prolonged disease
free interval
The time interval between removal of the primary mela-
noma and detection of metastatic disease is very variable
and can span many years, or even decades. The mecha-
nisms by which metastatic disease may be present but
remain clinically undetected for such prolonged periods,
presumably influenced by interactions between the mela-
noma phenotype and the patient’s immune system, have
not received sufficient attention to date [59]. A better
understanding of the molecular cross-talk between tumor
cells, immune cells and the extracellular matrix in sec-
ondary sites, and how these regulate metastatic disease
progression, may lead to improved therapeutic strategies to
eradicate them or at least to induce or maintain dissemi-
nated tumor cells in a clinically-silent chronic disease
(‘‘dormant’’) state [60]. Adjuvant therapies, such as anti-
bodies that target metastatic melanoma cells are of con-
siderable interest [61, 62]. We performed correlation
analyses of antigen levels and the DFI (time from primary
diagnosis and detection of LN metastasis) to identify sur-
face antigen signatures associated with melanoma pro-
gression following prolonged disease-free (latent)
intervals.
Cell adhesion markers on enriched melanoma cells
(CD45-) correlate with longer disease-free intervals
The tumor microenvironment is a critical regulator of
cancer progression [60] and integrin-mediated interactions
between tumor cells and the extracellular matrix (ECM)
modulate the metastatic potential of tumor cells [63]. We
identified higher levels of the integrins CD29 and CD49c
on CD45- cells from metastatic LN tumors following a
prolonged DFI. Integrins are trans-membrane proteins
involved in cell adhesion, migration, proliferation and
signal transduction [64]. To escape a dormant state, tumor
cells must engage with the ECM via integrin receptor(s),
inducing signalling that leads to cytoskeletal reorganisation
and cell proliferation [60]. Integrin-containing complexes
interact with the ECM via actin filaments and focal adhe-
sion complexes, but also regulate, and are regulated by
receptor tyrosine kinases and other signalling pathways
[65, 66]. There is growing evidence implicating CD29
(integrin b1) heterodimers and signal transducers in regu-
lating tumor cell dormancy [63, 67–69]. Other antigens
involved in cell adhesion were increased on CD45- cells
following reactivated dormant disease, including CD56,
CD63 and CD107a.
Reduced levels of T-cell activation markers in LN
metastases resected after a prolonged disease-free interval
Metastatic melanoma is highly immunogenic, however
attempts to boost patient immunity and/or vaccinate against
melanoma have had limited success [70, 71]. Melanoma
cells are capable of immune subversion within a tumor or
draining LN by altering dendritic cell function through the
secretion of tumor-derived cytokines [72], leading to the
generation of suppressive and regulatory T-cells [73].
T-cell-mediated immunity is an important component in
the regulation of tumor dormancy [74]. In transgenic
mouse models, CD8? T-cells appear to halt the expansion
of disseminated melanoma cells in the bone marrow and
LNs [75]. Moreover, CD8? T-cells appear to have distinct
roles in controlling disease progression and metastatic
spread [76], suggesting that the effect of immune cells on
melanoma dormancy might depend on the microenviron-
ment [59]. Here we found a significant correlation between
reduced CD8 T-cells in patients with stage III metastatic
disease resected following a long DFI. Interestingly, 7
other antigens involved in T-cell immunity were reduced in
these patients, including CD7, CD43, CD54 [77], CD56
[78], CD103 [79], CD134 [17] and CD166 [80]. Decreased
CD134 levels on CD4? T-cells in sentinel LNs draining
primary melanomas correlated with more advanced tumor
features and nodal involvement [17]. Overall, these results
suggest that a local immuno-suppressive LN microenvi-
ronment may induce the reactivation and expansion of
dormant tumor cells.
Conclusions
Surface markers prognostic for survival identified here
require validation in a larger, independent cohort of stage
III melanoma patients. The significant findings of low CD9
(DMFS) and high CD55 (DMFS) and CD39 (DMFS and
OS) levels on CD45? leukocytes with better survival out-
comes on multivariate analysis warrants further study.
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Enhanced expression of the adhesion markers CD29,
CD49c, CD56, CD63 and CD107a on CD45- melanoma
cells and loss of T-cell-related immunity is implicated in
melanoma progression following a prolonged period in
which metastatic disease has remained clinically silent/
undetected. A better understanding of the interplay of
melanoma cells, the immune system and the factors that
control them will enable more accurate prognostication and
furthermore, provide new therapeutic approaches to treat
this complex, heterogeneous cancer.
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